Mevrometostat

DRUG2 trials

Sponsors

Pfizer, Prostate Cancer Clinical Trials Consortium

Conditions

Cancer of the ProstateHormone Sensitive Prostate CancerMetastatic Castrate Resistant Prostate Cancer (mCRPC)Metastatic Castration Sensitive Prostate Cancer (mCSPC)Prostate CancerProstate Cancer (Adenocarcinoma)

Phase 2

A Study of Mevrometostat With Enzalutamide in People With Prostate Cancer Who Have Previously Received Androgen Receptor Pathway Inhibitor Therapy

Not yet recruitingNCT07592910

Prostate Cancer Clinical Trials ConsortiumMetastatic Castrate Resistant Prostate Cancer (mCRPC), Prostate Cancer (Adenocarcinoma)

Start: 2026-08-01End: 2029-08-01Target: 60Updated: 2026-05-18

Phase 3

This Study Will Explore Whether a Combination of the Investigational Drug Mevrometostat (PF-06821497) and Enzalutamide Will Work Better Than Taking Enzalutamide Alone in Participants With mCSPC Who Are ARPI naïve.

RecruitingNCT07028853

PfizerCancer of the Prostate, Hormone Sensitive Prostate Cancer, Metastatic Castration Sensitive Prostate Cancer (mCSPC) +1

Start: 2025-09-28End: 2034-12-08Target: 1000Updated: 2026-08-14